Pharming discontinues funding of DNage
(Thomson Reuters ONE) -
Leiden, The Netherlands, 31 January, 2011. Biotech company Pharming Group NV
("Pharming") (NYSE Euronext: PHARM) today announces that it has discontinued the
funding of DNage.
In July 2010, Pharming announced the completion of the spin-off of its
subsidiary DNage. As part of the spin- off agreement, Pharming agreed to provide
DNage with an undisclosed,limited bridge funding for a specified term, to allow
DNage time to seek new investors. DNage has been unable to secure new investors
and its shareholders have now decided to put DNage into voluntary liquidation.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of unmet
medical needs. Ruconest(TM) (Rhucin® in non-European territories) is a
recombinant human C1 inhibitor approved for the treatment of angioedema attacks
in patients with HAE in all 27 EU countries plus Norway, Iceland and
Liechtenstein. The product is also under development for follow-on indications,
i.e. antibody-mediated rejection (AMR) and delayed graft function (DGF)
following kidney transplantation. The advanced technologies of the Company
include innovative platforms for the production of protein therapeutics,
technology and processes for the purification and formulation of these products.
Additional information is available on the Pharming website,www.pharming.com.
This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.
Contact:
Karl Keegan, Chief Financial Officer Pharming Group NV., T: +31 (0)71 52 47 400
or E:k.keegan(at)pharming.com
Press release (PDF):
http://hugin.info/132866/R/1483858/418994.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE
[HUG#1483858]
Unternehmensinformation / Kurzprofil:
Datum: 31.01.2011 - 16:55 Uhr
Sprache: Deutsch
News-ID 50893
Anzahl Zeichen: 2736
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 320 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pharming discontinues funding of DNage"
steht unter der journalistisch-redaktionellen Verantwortung von
Pharming Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
